Exclusive Option Agreement May Catch Some Shorts
DENVER, Colo., Dec 1, 2023 (247marketnews.com)- NLS Pharmaceutics Ltd. (NASDAQ:NLSP) announced, this morning, that it entered into an exclusive worldwide option agreement with Aexon Labs, under which NLS may acquire global development and commercialization rights to Aexon Labs’ Dual Orexin Receptor Agonists platform, new molecular entities, highly selective dual oral orexin-1 and orexin-2 receptor agonists (OX1R and OX2R) with potential applications in the treatment of narcolepsy and idiopathic hypersomnia, as well as neuro-degenerative disorders such as Parkinson’s and Alzheimer’s disease.
NLS Pharmaceutics is trading at $0.4923, up $0.0724 (+17.24%), on 5.1M shares traded
Its 52-week range is $0.26 to $1.88. This hit its 52-week low mid-November, but it’s reversing that trend. It’s already more than doubled its 52-week high volume mark, but it’s pulled way back from this morning’s premarket high of $0.8985.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
The stocks and strategies discussed are simply ideas only and are in no way financial advice or recommendations. The author may or may not at any time be holding securities discussed. The author may or may not enter trades in the stocks mentioned. Some positions in mentioned stocks may already be held or are being adjusted or are simply examples, ideas or discussion topics. You are always trading at your own risk.
Please go to 247marketnews.com or https://247marketnews.com/terms-disclaimer/ for further information.